Ezetimibe (Zetia)

FDA Approved

Cholesterol Absorption Inhibitor | Lipid Management On Cycle

Weight: 409.43 Da

Half-life: ~22 hours

5 studies

2019 latest

2 recent

FDA Approved

Dose 10 mg/day

Frequency Once daily

Cycle Ongoing (duration of AAS cycle or chronic use)

Storage Room temperature (68-77F). Protect from moisture and light.

Accumulation Plotter

Community Research

Join others researching Ezetimibe — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings

Discussion Questions & experiences

Submit Your Findings Contribute your research data

Ezetimibe is a selective cholesterol absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) protein in the brush border of the small intestine, preventing dietary and biliary cholesterol from entering the bloodstream. Approved by the FDA in 2002, it occupies a unique niche among lipid-lowering agents by targeting intestinal cholesterol uptake rather than hepatic cholesterol synthesis. In the context of anabolic steroid use, ezetimibe has become a go-to ancillary compound for managing the dyslipidemia that accompanies many AAS cycles, particularly oral steroids like oxandrolone (Anavar) and stanozolol (Winstrol) that are notorious for crashing HDL cholesterol and elevating LDL. While statins remain the first-line treatment for hypercholesterolemia in the general population, ezetimibe is frequently used alone or stacked with a statin by steroid users seeking to mitigate cycle-induced lipid damage without adding yet another hepatotoxic compound to the mix.

Mechanism of Action

Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle. By blocking this transporter, ezetimibe reduces cholesterol delivery to the liver, which in turn upregulates hepatic LDL receptor expression to compensate for the reduced cholesterol supply. This upregulation increases LDL clearance from the bloodstream. The mechanism is entirely complementary to statins, which inhibit HMG-CoA reductase to reduce hepatic cholesterol synthesis. When the liver is deprived of cholesterol from both sources simultaneously, the LDL-lowering effect is significantly amplified. Ezetimibe undergoes glucuronidation in the intestinal wall and liver to form its active metabolite, ezetimibe-glucuronide, which is also pharmacologically active and participates in enterohepatic recirculation, contributing to the drug's prolonged duration of action.

01 Reduces LDL cholesterol by 15-20% as monotherapy

02 Complementary mechanism to statins allows additive LDL reduction of 25% when combined

03 Minimal hepatotoxicity, making it suitable alongside hepatotoxic oral AAS

04 Simple once-daily dosing with no titration required

05 No significant impact on CoQ10 levels (unlike statins)

06 Well tolerated with a side effect profile comparable to placebo in clinical trials

07 Proven cardiovascular outcome benefit when added to statin therapy (IMPROVE-IT trial)

08 Helps manage the severe lipid disruption caused by oral steroids like Anavar and Winstrol

Molecular Data

Molecular Weight

409.43 Da

Type

Azetidinone (C24H21F2NO3)

Peak 0.0 mcg

Trough 0.0 mcg

SS Peak 0.0 mcg

SS Trough 0.0 mcg

Research Indications

Lipid Management

Primary Hypercholesterolemia effective

FDA-approved for reduction of elevated total cholesterol and LDL-C in patients with primary hyperlipidemia, either as monotherapy or in combination with a statin. Reduces LDL by approximately 18% as monotherapy and provides an additional 25% reduction when added to ongoing statin therapy.

AAS-Induced Dyslipidemia moderate

Widely used off-label by anabolic steroid users to counteract the significant lipid disturbances caused by AAS, particularly oral 17-alpha-alkylated steroids. Oral compounds like oxandrolone can reduce HDL by 50% or more and elevate LDL substantially. Ezetimibe helps blunt LDL elevation while its non-hepatotoxic profile makes it preferable to statins during cycles involving liver-stressing orals.

Statin Combination Therapy most effective

When LDL targets are not achieved with statin monotherapy, adding ezetimibe provides a complementary mechanism of action. The IMPROVE-IT trial demonstrated that the combination of ezetimibe plus simvastatin reduced cardiovascular events compared to simvastatin alone in post-acute coronary syndrome patients.

Cardiovascular Risk Reduction

Secondary Prevention of Cardiovascular Events effective

The IMPROVE-IT trial established that adding ezetimibe to simvastatin therapy reduced the composite endpoint of cardiovascular death, major coronary events, and stroke by 6.4% over 7 years in patients with recent acute coronary syndrome. This was the first trial to demonstrate that a non-statin LDL-lowering agent provides incremental cardiovascular benefit.

Familial Hypercholesterolemia effective

Approved as adjunctive therapy for homozygous familial hypercholesterolemia (HoFH) in combination with statins. Also used in heterozygous FH when statin monotherapy is insufficient to reach LDL targets. Particularly useful in patients who cannot tolerate high-dose statins.

Dosing Protocols

Ezetimibe is administered exclusively by the oral route as a 10 mg tablet taken once daily. It can be taken with or without food, at any time of day, though consistent timing is recommended for adherence. The drug does not require dose titration, as the 10 mg dose is the only approved strength and has been shown to provide the optimal balance of efficacy and tolerability. Ezetimibe is extensively glucuronidated in the small intestine and liver, and the active parent compound and its glucuronide metabolite undergo enterohepatic recirculation, contributing to the long effective half-life.

Goal	Dose	Frequency	Route
Standard Lipid Management	10 mg/day	Once daily	Oral, with or without food
On-Cycle Lipid Support (AAS Users)	10 mg/day	Once daily, throughout cycle and into PCT	Oral, with or without food
Combination with Statin	10 mg/day ezetimibe + statin of choice	Once daily (ezetimibe can be taken same time as statin or separately)	Oral

Interactions

Statins

Ezetimibe and statins target cholesterol from complementary directions: ezetimibe blocks intestinal absorption while statins inhibit hepatic synthesis. The combination produces additive LDL reductions of 40-60% depending on the statin and dose. The IMPROVE-IT trial validated this combination with hard cardiovascular outcomes data. Rosuvastatin or atorvastatin are the preferred statin partners for maximal LDL lowering.

synergistic

Oxandrolone

A common pairing in the steroid community. Oxandrolone (Anavar) is notorious for severely suppressing HDL (often by 50% or more) and raising LDL. Ezetimibe helps mitigate the LDL component of this dyslipidemia without adding hepatic stress to an already liver-burdened cycle. While ezetimibe does not directly improve HDL, controlling LDL helps manage overall cardiovascular risk during Anavar cycles.

compatible

Fibrates

Fibrates (fenofibrate, gemfibrozil) primarily target triglycerides and can modestly raise HDL. Combining ezetimibe with fenofibrate is generally well tolerated and addresses different aspects of the lipid panel. However, gemfibrozil should be used with caution as it can increase ezetimibe exposure by inhibiting its glucuronidation. Monitor liver enzymes and watch for signs of gallstone formation, as both agents can increase biliary cholesterol saturation.

monitor

What to Expect

Week 1-2

Ezetimibe begins inhibiting intestinal cholesterol absorption within days. Early reductions in circulating LDL cholesterol may be detectable by the end of the second week. Side effects are uncommon, but mild GI discomfort may occur during the adjustment period.

Week 2-4

LDL cholesterol reductions become more pronounced as hepatic LDL receptor upregulation reaches a new steady state. Most of the drug's LDL-lowering effect is apparent by week 4. Lipid panel at this point will typically show a 15-20% reduction in LDL-C from baseline.

Month 1-3

Full steady-state lipid effects are established. On-cycle AAS users should see meaningful attenuation of LDL elevation compared to running the same cycle without ezetimibe. Total cholesterol and LDL should be noticeably lower than expected for the given AAS protocol.

Month 3+

Long-term use is well tolerated with sustained LDL reductions. If used alongside AAS, continue through post-cycle therapy and until bloodwork confirms lipid normalization. No significant long-term side effects or nutrient depletions are associated with extended ezetimibe use.

Side Effects & Safety

Common Side Effects

Gastrointestinal discomfort (diarrhea, abdominal pain) - mild and infrequent, reported at similar rates to placebo
Upper respiratory tract infection (reported in clinical trials but not clearly drug-related)
Fatigue and headache (uncommon, typically transient)

Stop Signs - Discontinue if:

Unexplained persistent muscle pain, tenderness, or weakness (especially if combined with a statin)
Signs of liver dysfunction: jaundice, dark urine, persistent nausea, right upper quadrant pain
Severe allergic reaction: facial swelling, difficulty breathing, widespread rash

Contraindications

Known hypersensitivity to ezetimibe or any component of the formulation
Active liver disease or unexplained persistent elevations in hepatic transaminases (when combined with a statin)
Pregnancy and breastfeeding (when used in combination with a statin)

Quality Checklist

Good Signs

Pharmaceutical-grade product from established manufacturer with valid NDC number
Proper labeling with 10 mg dosage strength, lot number, and expiration date
Tablets are uniform in appearance with no chips, cracks, or discoloration
Prescribed by licensed physician or obtained from licensed pharmacy
Generic ezetimibe from reputable manufacturer (patent expired, widely available)

Warning Signs

Sourced from unverified international online pharmacies
Compounded formulations without verification of potency and purity
Product stored in improper conditions (excessive heat or humidity)

Bad Signs

Tablets that are crumbling, discolored, or have an unusual odor
Product past its expiration date
No labeling, incorrect dosage strength, or missing lot/expiration information
Sourced without any verification from unregulated suppliers

References

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (IMPROVE-IT)

Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al.

The New England Journal of Medicine (2015)

Landmark trial of 18,144 patients demonstrating that adding ezetimibe to simvastatin after acute coronary syndrome reduced the primary composite endpoint (cardiovascular death, MI, unstable angina, coronary revascularization, or stroke) by 6.4% over a median of 6 years. First trial to prove that a non-statin lipid-lowering agent provides incremental cardiovascular benefit.
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions

Kosoglou, T., Statkevich, P., Johnson-Levonas, A.O., et al.

Clinical Pharmacokinetics (2005)

Comprehensive pharmacokinetic review describing ezetimibe's glucuronidation pathway, enterohepatic recirculation, and 22-hour effective half-life. Demonstrated minimal cytochrome P450 involvement, supporting its favorable drug interaction profile.
Efficacy and safety of ezetimibe monotherapy in hypercholesterolaemic patients: a meta-analysis

Pandor, A., Ara, R.M., Tumur, I., et al.

International Journal of Clinical Practice (2009)

Meta-analysis confirming ezetimibe monotherapy reduces LDL-C by approximately 18.6%, total cholesterol by 13.5%, and triglycerides by 8.1% with a side effect profile comparable to placebo. Supports use as monotherapy in statin-intolerant patients.
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol

Grundy, S.M., Stone, N.J., Bailey, A.L., et al.

Journal of the American College of Cardiology (2019)

Current ACC/AHA cholesterol management guidelines positioning ezetimibe as the preferred first add-on therapy when LDL-C goals are not met with maximally tolerated statin therapy, before escalation to PCSK9 inhibitors.
NPC1L1 and Cholesterol Transport

Altmann, S.W., Davis, H.R., Zhu, L., et al.

Biochimica et Biophysica Acta (2004)

Identification and characterization of NPC1L1 as the molecular target of ezetimibe, establishing the mechanism by which the drug selectively blocks intestinal cholesterol absorption at the brush border membrane of enterocytes.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.